Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low-quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs.

Embleema’s next building block is a Real-World Evidence (RWE) marketplace allowing patients to receive treatments and to connect with research. Sharing continuous, individual-patient level data will allow better monitoring of drugs in real-life and accelerate drug availability to patients.